|
業務類別
|
Biotechnology |
|
業務概覽
|
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity. |
| 公司地址
| 900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063 |
| 電話號碼
| +1 650 980-9099 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.biomeafusion.com |
| 員工數量
| 106 |
| Dr. Juan Pablo Frias, M.D. |
Chief Medical Officer and Head of Diabetes |
-- |
28/04/2025 |
| Mr. Rainer M. Erdtmann |
Director, President, Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer |
美元 489.60K |
27/03/2025 |
| Dr. Michael J. M. Hitchcock, PhD |
Director and Interim Chief Executive Officer |
-- |
27/03/2025 |
|
|
| Mr. Rainer M. Erdtmann |
Director, President, Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer |
27/03/2025 |
| Dr. Eric Aguiar, M.D. |
Lead Independent Director |
28/04/2025 |
| Dr. Elizabeth Faust, PhD |
Independent Director |
28/04/2025 |
| Ms. Sumita Ray, J.D. |
Independent Director |
28/04/2025 |
| Ms. Julianne Averill |
Director |
24/07/2025 |
| Dr. Michael J. M. Hitchcock, PhD |
Director and Interim Chief Executive Officer |
27/03/2025 |
|
|
|
|
